DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0090-9556/03/3111-1320-1326$20.00
DMD 31:1320-1326, 2003

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laurenzana, E. M.
Right arrow Articles by Owens, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laurenzana, E. M.
Right arrow Articles by Owens, S. M.

USE OF ANTI-(+)-METHAMPHETAMINE MONOCLONAL ANTIBODY TO SIGNIFICANTLY ALTER (+)-METHAMPHETAMINE AND (+)-AMPHETAMINE DISPOSITION IN RATS

Elizabeth M. Laurenzana, Kelly A. Byrnes-Blake1, Alessandra Milesi-Hallé, W. Brooks Gentry, D. Keith Williams, and S. Michael Owens

Department of Pharmacology and Toxicology (E.M.L., K.A.B.-B., A.M.-H., W.B.G., S.M.O.), Department of Anesthesiology (W.B.G.), and Department of Biostatistics (D.K.W.), University of Arkansas for Medical Sciences, Little Rock, Arkansas

These studies examined the effects of a high-affinity anti-(+)-methamphetamine monoclonal antibody (mAb; KD = 11 nM) on (+)-methamphetamine [(+)-METH] and (+)-amphetamine [(+)-AMP] serum and tissue disposition and serum protein binding following i.v. (+)-METH administration. Male Sprague-Dawley rats were pretreated with a buffer solution (control rats) or with anti-(+)-METH mAb [equimolar in binding sites to the (+)-METH dose]. The next day, both groups received a 1 mg/kg i.v. (+)-METH dose. At various time points after (+)-METH administration, rats were sacrificed (n = 3 per time point), and serum and tissues were collected. (+)-METH serum protein binding was increased from ~5% in controls to ~88 to 99% in the mAb-treated rats. The (+)-METH area under the concentration versus time curves from 0 to 4.5 h (AUC04.5 h) in mAb-treated rats showed an increase of >6600% for serum and a decrease of >60% for brain, compared with buffer-treated controls. Differential effects of anti-METH mAb on (+)-METH concentrations were observed in other tissues. For example, in the liver, anti-(+)-METH mAb caused significant increases in (+)-METH concentrations. The AUC04.5 h for (+)-AMP, a pharmacologically active metabolite, was decreased by ~50% in all tissues examined. These data show that pretreatment with an anti-(+)-METH mAb can significantly alter the disposition of (+)-METH and (+)-AMP in rats. Since the mAb has no significant cross-reactivity with (+)-AMP, the data suggest that the mAb reduced (+)-METH metabolic clearance through high-affinity binding to (+)-METH. Finally, rapidly equilibrating tissues, like the brain, appear to be preferentially protected by the mAb.


Address correspondence to: Dr. Elizabeth M. Laurenzana, Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, 4301 West Markham, Slot 611, Little Rock, AR 72205. E-mail: laurenzanaelizabeth{at}uams.edu or owenssamuelm{at}uams.edu




This article has been cited by other articles:


Home page
Mol. Interv.Home page
E. C. Peterson and S. M. Owens
Designing Immunotherapies to Thwart Drug Abuse
Mol. Interv., June 1, 2009; 9(3): 119 - 124.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. C. Peterson, M. Gunnell, Y. Che, R. L. Goforth, F. I. Carroll, R. Henry, H. Liu, and S. M. Owens
Using Hapten Design to Discover Therapeutic Monoclonal Antibodies for Treating Methamphetamine Abuse
J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 30 - 39.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. B. Norman, M. R. Tabet, M. K. Norman, W. R. Buesing, A. J. Pesce, and W. J. Ball
A Chimeric Human/Murine Anticocaine Monoclonal Antibody Inhibits the Distribution of Cocaine to the Brain in Mice
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 145 - 153.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. R. Pentel, M. B. Dufek, S. A. Roiko, M. G. LeSage, and D. E. Keyler
Differential Effects of Passive Immunization with Nicotine-Specific Antibodies on the Acute and Chronic Distribution of Nicotine to Brain in Rats
J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 660 - 666.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. E. McMillan, W. C. Hardwick, M. Li, M. G. Gunnell, F. I. Carroll, P. Abraham, and S. M. Owens
Effects of Murine-Derived Anti-Methamphetamine Monoclonal Antibodies on (+)-Methamphetamine Self-Administration in the Rat
J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1248 - 1255.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.